Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
Previous Symbol
CUSIP69512710
Phone973-254-3560
Debt
Debt-to-Equity Ratio0.95
Current Ratio8.66
Quick Ratio7.83
Price-To-Earnings
Trailing P/E Ratio-79.16
Forward P/E Ratio2,295.50
P/E Growth80
Sales & Book Value
Annual Sales$286.63 million
Price / Sales6.58
Cash Flow$0.0603 per share
Price / Cash761.91
Book Value$6.89 per share
Price / Book6.66
Profitability
EPS (Most Recent Fiscal Year)($0.58)
Net Income$-42,610,000.00
Net Margins-1.30%
Return on Equity2.74%
Return on Assets1.24%
Miscellaneous
Employees489
Outstanding Shares41,110,000
Market Cap$1.92 billion
OptionableOptionable
Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions
What is Pacira Pharmaceuticals' stock symbol?
Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."
How were Pacira Pharmaceuticals' earnings last quarter?
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) posted its quarterly earnings results on Thursday, November, 1st. The company reported $0.31 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.40. The company earned $83.45 million during the quarter, compared to the consensus estimate of $79.87 million. Pacira Pharmaceuticals had a positive return on equity of 2.74% and a negative net margin of 1.30%. The business's quarterly revenue was up 23.9% on a year-over-year basis. During the same period last year, the business earned $0.11 EPS. View Pacira Pharmaceuticals' Earnings History.
When is Pacira Pharmaceuticals' next earnings date?
What guidance has Pacira Pharmaceuticals issued on next quarter's earnings?
Pacira Pharmaceuticals updated its FY 2018 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $325-330 million, compared to the consensus revenue estimate of $326.84 million.
What price target have analysts set for PCRX?
18 Wall Street analysts have issued 1-year price objectives for Pacira Pharmaceuticals' stock. Their predictions range from $41.00 to $90.00. On average, they expect Pacira Pharmaceuticals' stock price to reach $54.5625 in the next year. This suggests a possible upside of 18.8% from the stock's current price. View Analyst Price Targets for Pacira Pharmaceuticals.
What is the consensus analysts' recommendation for Pacira Pharmaceuticals?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacira Pharmaceuticals.
What are Wall Street analysts saying about Pacira Pharmaceuticals stock?
Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We valued Pacira based on an equally weighted blend of discounted cash flow analysis and sum-of-the-parts valuation. This analysis generates our $43 price target, supporting our Neutral rating." (11/1/2018)
- 2. According to Zacks Investment Research, "Pacira’s top line mainly comprises contribution from its marketed product-Exparel. It is making efforts to expand Exparel's label. In April 2018, the FDA approved Pacira’s sNDA seeking expansion of the Exparel label to include administration via nerve block for prolonged regional analgesia. However, the company is heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. This is a concern for the company. Exparel also competes with well-established products for postsurgical pain management." (7/15/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back)." (7/10/2018)
Has Pacira Pharmaceuticals been receiving favorable news coverage?
News stories about PCRX stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 3.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the company's share price in the immediate future.
Who are some of Pacira Pharmaceuticals' key competitors?
Some companies that are related to Pacira Pharmaceuticals include Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), SAGE Therapeutics (SAGE), Amarin (AMRN), United Therapeutics (UTHR), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO) and HUTCHISON CHINA/S (HCM).
Who are Pacira Pharmaceuticals' key executives?
Pacira Pharmaceuticals' management team includes the folowing people:
- Mr. David M. Stack, Chairman & CEO (Age 68)
- Mr. Charles A. Reinhart III, Chief Financial Officer (Age 57)
- Dr. Richard Scranton M.D., MPH, Chief Scientific Officer (Age 57)
- Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 44)
- Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 39)
Who are Pacira Pharmaceuticals' major shareholders?
Pacira Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Partner Fund Management L.P. (6.81%), Macquarie Group Ltd. (5.97%), HealthCor Management L.P. (4.73%), Schroder Investment Management Group (2.38%), Baillie Gifford & Co. (1.95%) and Elk Creek Partners LLC (1.76%). Company insiders that own Pacira Pharmaceuticals stock include Andreas Wicki, Charles A Reinhart III, David M Stack, Gary W Pace, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.
Which institutional investors are selling Pacira Pharmaceuticals stock?
PCRX stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP, HealthCor Management L.P., Elk Creek Partners LLC, Partner Fund Management L.P., Schroder Investment Management Group, Penn Capital Management Co. Inc., Mesirow Financial Investment Management Equity Management and Peregrine Capital Management LLC. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Andreas Wicki, Charles A Reinhart III, David M Stack, James B Jones, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals.
Which institutional investors are buying Pacira Pharmaceuticals stock?
PCRX stock was acquired by a variety of institutional investors in the last quarter, including Castleark Management LLC, Baillie Gifford & Co., Morgan Stanley, TIAA CREF Investment Management LLC, Point72 Asset Management L.P., Macquarie Group Ltd., Chicago Equity Partners LLC and Prudential Financial Inc.. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Gary W Pace, Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals.
How do I buy shares of Pacira Pharmaceuticals?
Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacira Pharmaceuticals' stock price today?
One share of PCRX stock can currently be purchased for approximately $45.91.
How big of a company is Pacira Pharmaceuticals?
Pacira Pharmaceuticals has a market capitalization of $1.92 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe.
What is Pacira Pharmaceuticals' official website?
How can I contact Pacira Pharmaceuticals?
Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]
MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
